SARS-CoV-2 Vaccines Beyond the Pandemic Era

COVID-19 inactivated booster vaccines elicit strong protection against SARS-CoV-2 wild-type and Omicron variant in patients with breast cancer

• Xiaomeng Li
• Yali Xu
• Haolong Li
• Linrong Li
• Yongmei Liu
• Haoting Zhan
• Qiang Sun
• Yongzhe Li

Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months

• Seçil Yılmaz
• Ahmet Eken
• zafer sezer
• Burcu Şen Bağcı
• Şerife Erdem
• Medine Doğan Sarıkaya
• Büşra Kaplan
• Ahmet Inal
• Adnan Bayram
• 8 more
• Aykut Ozdarendeli

Impact of QazVac vaccination on clinical manifestations and immune responses in post—COVID syndrome: a cross-sectional study

• Akzhan M. Madenbayeva
• Saulesh S. Kurmangaliyeva
• Saltanat T. Urazayeva
• Kairat B. Kurmangaliyev
• Yerlan Sh. Bazargaliyev
• Khatimya I. Kudabayeva

Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls

• Vitor Gabriel Lopes da Silva
• Gabriela Justamante Händel Schmitz
• Kathleen E. Sullivan
• Júlia Barbate
• Maria Izabel de Haro Azinar
• Carolina Sanchez Aranda
• Maria Isabel de Moraes-Pinto

Assessment of serum biomarker changes following the COVID-19 pandemic and vaccination: a cohort study in Sylhet, Bangladesh

• Shangida Akther
• Fairoz Samiha
• Sabrina Amita Sony
• Mohammad Anamul Haque
• Mohammad Abul Hasnat
• S. M. Saiful Islam
• Shamim Ahmed
• Mohammad Abdullah-Al-Shoeb

Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients

• Vincenzo Raimondi
• Paola Storti
• Rosanna Vescovini
• Valentina Franceschi
• Denise Toscani
• Laura Notarfranchi
• Anna Benedetta Dalla Palma
• Nicolas Thomas Iannozzi
• Sergio Minesso
• 4 more
• Nicola Giuliani

XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants

• Matthew E. Levy
• Vanessa Chilunda
• Phillip R. Heaton
• Deran McKeen
• Jason D. Goldman
• Richard E. Davis
• Cynthia A. Schandl
• William B. Glen
• Lisa M. McEwen
• 13 more
• Shishi Luo

Safety and immunogenicity of Ad5-nCoV administered intradermally by needle-free injector in rats

• Li Chen
• Xiaoyin Zhang
• Lairun Jin
• Lihua Hou
• Fengcai Zhu
• Jingxin Li

Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O)

• Pia Gattinger
• Luibov I. Kozlovskaya
• Alexander S. Lunin
• Olga S. Gancharova
• Dina I. Sirazova
• Vasiliy D. Apolokhov
• Egor S. Chekina
• Ilya V. Gordeychuk
• Alexander V. Karaulov
• 1 more
• Aydar A. Ishmukhametov

Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain)

• Ana C. Montagud
• Raul Moragues
• Nancy Vicente-Alcalde
• Emilia Montagud
• José Antonio Hurtado-Sánchez
• José Tuells

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination

• Maaweya Awadalla
• Halah Z. AlRawi
• Rahaf A. Henawi
• Fawziya Barnawi
• Haitham Alkadi
• Ahmed Alyami
• Ammar Alsughayir
• Alyazeed S. Alsaif
• Ayman Mubarak
• 1 more
• Bandar Alosaimi

Expression of concern: Evaluation of post-COVID mortality risk in cases classified as severe acute respiratory syndrome in Brazil: a longitudinal study for medium and long term